Login to Your Account

Crohn's Drug Fails In Phase II; Millennium Awaits More Data

By Randall Osborne

Tuesday, September 17, 2002
Although its treatment for Crohn's disease missed the primary endpoint in a Phase II trial, Millennium Pharmaceuticals Inc. said the drug hit a secondary endpoint and the company is awaiting results from another Phase II study, this one for ulcerative colitis, with the monoclonal antibody MLN02. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription